Literature DB >> 17301136

Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.

Shaun K Rodriguez1, Abdoulaye Dieng Sarr, Adam MacNeil, Seema Thakore-Meloni, Aissatou Gueye-Ndiaye, Ibrahima Traoré, Mamadou C Dia, Souleymane Mboup, Phyllis J Kanki.   

Abstract

Neutralizing antibody responses against heterologous isolates in human immunodeficiency virus type 1 (HIV-1) and HIV-2 infections were compared, and their relationships with established clinical markers of progression were examined. Neutralizing responses against 7 heterologous primary isolates and 1 laboratory strain were compared between 32 untreated HIV-1-infected subjects and 35 untreated HIV-2-infected subjects using a pseudotyped reporter virus assay. The breadth of the neutralizing response, defined as the proportion of panel viruses positively neutralized by patient plasma, was significantly greater among HIV-2-infected subjects than among HIV-1-infected subjects. Notably, for fully one-third of HIV-2 subjects, all viruses were effectively neutralized in our panel. Magnitudes of responses, defined as reciprocal 50% inhibitory concentration (IC(50)) titers for positive reactions, were significantly greater among HIV-1-infected subjects than among HIV-2-infected subjects. When plasma samples from HIV-1 patients were tested for cross-neutralization of HIV-2 and vice versa, we found that these intertype responses are very rare and their prevalences comparable in both HIV-1 and HIV-2 infection. The significantly higher magnitude of heterologous responses for HIV-1 compared to HIV-2 prompted us to examine associations with viremia, which is known to be significantly higher in HIV-1 infection. Importantly, there was a significant positive correlation between the IC(50) titer and viral load within both the HIV-1 and HIV-2 groups, suggesting heterologous antibodies may be driven by viral replication. We conclude that HIV-2 infection is characterized by a broad, low-magnitude intratype neutralization response, while HIV-1 is characterized by a narrower but higher-magnitude intratype response and that a significant positive association between the IC(50) titer and viremia is common to both HIV-1 and HIV-2 infections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301136      PMCID: PMC1900200          DOI: 10.1128/JVI.02789-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques.

Authors:  J L Heeney; V J Teeuwsen; M van Gils; W M Bogers; C De Giuli Morghen; A Radaelli; S Barnett; B Morein; L Akerblom; Y Wang; T Lehner; D Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

2.  HIV-2 antisera cross-neutralize HIV-1.

Authors:  R A Weiss; P R Clapham; J N Weber; D Whitby; R S Tedder; T O'Connor; S Chamaret; L Montagnier
Journal:  AIDS       Date:  1988-04       Impact factor: 4.177

3.  Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection.

Authors:  E Björling; G Scarlatti; A von Gegerfelt; J Albert; G Biberfeld; F Chiodi; E Norrby; E M Fenyö
Journal:  Virology       Date:  1993-03       Impact factor: 3.616

4.  Development of the antibody response in acute HIV-1 infection.

Authors:  Marlén M I Aasa-Chapman; Anna Hayman; Philippa Newton; David Cornforth; Ian Williams; Persephone Borrow; Peter Balfe; Aine McKnight
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

5.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

Authors:  J Albert; B Abrahamsson; K Nagy; E Aurelius; H Gaines; G Nyström; E M Fenyö
Journal:  AIDS       Date:  1990-02       Impact factor: 4.177

6.  Clinical, hematologic, and immunologic cross-sectional evaluation of individuals exposed to human immunodeficiency virus type-2 (HIV-2).

Authors:  R G Marlink; D Ricard; S M'Boup; P J Kanki; J L Romet-Lemonne; I N'Doye; K Diop; M A Simpson; F Greco; M J Chou
Journal:  AIDS Res Hum Retroviruses       Date:  1988-04       Impact factor: 2.205

7.  Prevalence and risk determinants of human immunodeficiency virus type 2 (HIV-2) and human immunodeficiency virus type 1 (HIV-1) in west African female prostitutes.

Authors:  P Kanki; S M'Boup; R Marlink; K Travers; C C Hsieh; A Gueye; C Boye; J L Sankalé; C Donnelly; W Leisenring
Journal:  Am J Epidemiol       Date:  1992-10-01       Impact factor: 4.897

8.  Biological and molecular variability of human immunodeficiency virus type 2 isolates from The Gambia.

Authors:  T F Schulz; D Whitby; J G Hoad; T Corrah; H Whittle; R A Weiss
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

9.  Cellular and plasma viral load in patients infected with HIV-2.

Authors:  F Simon; S Matheron; C Tamalet; I Loussert-Ajaka; S Bartczak; J M Pépin; C Dhiver; E Gamba; C Elbim; J A Gastaut
Journal:  AIDS       Date:  1993-11       Impact factor: 4.177

10.  Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies.

Authors:  M Arendrup; C Nielsen; J E Hansen; C Pedersen; L Mathiesen; J O Nielsen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992
View more
  25 in total

1.  Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.

Authors:  Gülsen Ozkaya Sahin; Birgitta Holmgren; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Joakim Esbjörnsson; Fredrik Månsson; Sören Andersson; Hans Norrgren; Peter Aaby; Marianne Jansson; Eva Maria Fenyö
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity.

Authors:  Mohammad M Sajadi; Yongjun Guan; Anthony L DeVico; Michael S Seaman; Mian Hossain; George K Lewis; Robert R Redfield
Journal:  J Acquir Immune Defic Syndr       Date:  2011-05-01       Impact factor: 3.731

Review 3.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

4.  The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1.

Authors:  Antoine Chaillon; Thierry Wack; Martine Braibant; Laurent Mandelbrot; Stéphane Blanche; Josiane Warszawski; Francis Barin
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

5.  Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection.

Authors:  Rui Kong; Hui Li; Frederic Bibollet-Ruche; Julie M Decker; Natalie N Zheng; Geoffrey S Gottlieb; Nancy B Kiviat; Papa Salif Sow; Ivelin Georgiev; Beatrice H Hahn; Peter D Kwong; James E Robinson; George M Shaw
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

6.  The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.

Authors:  John B Lynch; Ruth Nduati; Catherine A Blish; Barbra A Richardson; Jennifer M Mabuka; Zahra Jalalian-Lechak; Grace John-Stewart; Julie Overbaugh
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

7.  Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.

Authors:  José Maria Marcelino; Pedro Borrego; Cheila Rocha; Helena Barroso; Alexandre Quintas; Carlos Novo; Nuno Taveira
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

8.  Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.

Authors:  Gülşen Özkaya Şahin; Birgitta Holmgren; Enas Sheik-Khalil; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Fredrik Månsson; Hans Norrgren; Peter Aaby; Eva Maria Fenyö; Marianne Jansson
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

9.  Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression.

Authors:  Anne Piantadosi; Dana Panteleeff; Catherine A Blish; Jared M Baeten; Walter Jaoko; R Scott McClelland; Julie Overbaugh
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

10.  Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease.

Authors:  Rita Cavaleiro; António P Baptista; Rui S Soares; Rita Tendeiro; Russell B Foxall; Perpétua Gomes; Rui M M Victorino; Ana E Sousa
Journal:  PLoS Pathog       Date:  2009-11-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.